Based on our prediction of Rbfox2 as a tumor suppressor from our in vivo screen and our observation of decreased RBFOX2 in PDX-derived cell lines from metastatic PDAC, we further investigated the potential role of RBFOX2 downregulation in promoting pancreatic cancer progression. This evidence concerns the gene RBFOX2 and familial pancreatic carcinoma.